NASDAQ$CERS
Cerus Corp · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Cerus reported a revenue increase driven by product revenue growth and raised full year product revenue guidance.
Cerus Corporation announced its first quarter 2021 financial results, reporting a 20% increase in total revenue compared to the prior year period. Product revenue grew due to increased demand for INTERCEPT platelet products in the U.S. The company also raised its full year product revenue guidance to $110 million to $114 million.
- Total revenue for Q1 2021 was $29.6 million, a 20% increase year-over-year.
- Product revenue for Q1 2021 was $23.4 million, a 26% increase year-over-year.
- The company increased its 2021 annual product revenue guidance to a range of $110 million to $114 million.
- Cash, cash equivalents, and short-term investments totaled $132 million as of March 31, 2021.
Headline financials
Revenue & EPS history
Cerus · Revenue · Quarterly
$23.4M
Revenue by segment
Cerus · $29.6M total across 2 segments · Q1 2021
- Product Revenue$23.4M—79.1%
- Government Contract Revenue$6.19M—20.9%
Forward guidance
Cerus expects 2021 product revenue to be in the range of $110 million to $114 million, representing approximately 20% to 24% growth compared to 2020 reported product revenue.
Tailwinds
- Increased demand for INTERCEPT platelet products in the U.S.
- Adoption from the top five blood center networks in the country.
- Potential regulatory approval for the red blood cell system.
- Building demand for the INTERCEPT Blood System.
- INTERCEPT Fibrinogen Complex eligible for incremental payment via a New Technology Add-On Payment (NTAP)
Headwinds
- Risks associated with commercialization and market acceptance of the INTERCEPT Blood System.
- Risks associated with the ultimate duration and severity of the COVID-19 pandemic.
- Risks related to Fresenius Kabi’s efforts to assure an uninterrupted supply of platelet additive solution (PAS).
- Risks related to the uncertain and time-consuming development and regulatory process.
- Risks associated with Cerus’ lack of experience in marketing products directly to hospitals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+27.5%
Q3 2017
Best reaction
-19.6%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +34.9% | +58.3% | |
| Q4 2025 | -17.3% | -23.7% | -26.5% | |
| Q3 2025 | -2.8% | +0.0% | +21.4% | |
| Q2 2025 | +0.8% | -2.3% | +3.9% | |
| Q1 2025 | +2.3% | +0.0% | -2.3% | |
| Q4 2024 | -5.2% | -5.7% | -12.1% | |
| Q3 2024 | -7.6% | -8.2% | +8.8% | |
| Q1 2024 | -5.8% | +7.6% | +4.1% | |
| Q4 2023 | +14.2% | +6.6% | -10.8% | |
| Q3 2023 | +25.4% | +25.4% | +21.0% | |
| Q2 2023 | -17.8% | -26.3% | -35.4% | |
| Q1 2023 | -0.9% | -6.1% | -1.7% | |
| Q4 2022 | -7.0% | +2.1% | -1.4% | |
| Q3 2022 | +7.7% | +6.0% | +18.9% | |
| Q2 2022 | -4.5% | -12.7% | -32.8% | |
| Q1 2022 | +2.9% | -2.7% | -2.3% | |
| Q4 2021 | -2.1% | +8.6% | +3.6% | |
| Q3 2021 | +14.5% | +16.0% | +1.5% | |
| Q2 2021 | +21.1% | +21.9% | +28.2% | |
| Q1 2021 | +2.7% | +4.8% | -7.7% | |
| Q4 2020 | -8.6% | -3.9% | -11.3% | |
| Q3 2020 | -5.4% | -0.4% | +18.6% | |
| Q2 2020 | -1.8% | -4.7% | -17.7% | |
| Q1 2020 | +2.1% | +5.2% | +12.5% | |
| Q4 2019 | -1.0% | -6.0% | -39.2% | |
| Q3 2019 | -4.4% | -3.7% | -4.6% | |
| Q2 2019 | -8.7% | -13.5% | -8.2% | |
| Q1 2019 | -12.3% | -15.2% | -27.3% | |
| Q4 2018 | +2.8% | +6.5% | -3.7% | |
| Q3 2018 | -4.9% | -13.4% | -21.6% | |
| Q2 2018 | -5.9% | -4.8% | +4.1% | |
| Q1 2018 | +11.9% | +17.1% | +17.8% | |
| Q4 2017 | +2.1% | +7.5% | +9.0% | |
| Q3 2017 | +27.5% | +26.4% | +40.9% | |
| Q2 2017 | +3.6% | +7.1% | +6.7% | |
| Q1 2017 | -19.6% | -28.3% | -44.5% | |
| Q4 2016 | -7.8% | +5.0% | +0.7% | |
| Q3 2016 | +6.4% | +15.0% | +10.2% | |
| Q2 2016 | +1.8% | -4.5% | -11.3% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +0.5% | — | — | |
| Q3 2015 | +4.5% | — | — | |
| Q2 2015 | -2.5% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | +4.8% | — | — | |
| Q1 2014 | +4.4% | — | — | |
| Q4 2013 | -15.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | +6.7% | — | — | |
| Q1 2013 | -9.7% | — | — | |
| Q4 2012 | +14.0% | — | — | |
| Q3 2012 | -1.9% | — | — | |
| Q2 2012 | -2.7% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2009 | +0.8% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2010 | -2.8% | — | — | |
| Q2 2011 | -2.8% | — | — | |
| Q4 2010 | -2.8% | — | — | |
| Q1 2010 | -2.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro